(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 19.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Amicus Therapeutics's revenue in 2025 is $528,295,000.On average, 4 Wall Street analysts forecast FOLD's revenue for 2025 to be $188,939,579,374, with the lowest FOLD revenue forecast at $186,678,204,704, and the highest FOLD revenue forecast at $190,546,700,988. On average, 4 Wall Street analysts forecast FOLD's revenue for 2026 to be $228,925,545,426, with the lowest FOLD revenue forecast at $224,603,873,860, and the highest FOLD revenue forecast at $237,115,713,276.
In 2027, FOLD is forecast to generate $261,504,946,715 in revenue, with the lowest revenue forecast at $253,297,972,364 and the highest revenue forecast at $268,789,964,465.